HCA

• The commercial paper notes are unsecured and unconditionally guaranteed by HCA Healthcare, Inc. (the Parent Guarantor).
• Other terms and conditions of the program remain as previously described in the June 10, 2025 Form 8-K.
• The notes and related guarantee have not been and will not be registered under the Securities Act of 1933 or state securities laws.
• The report was filed under Item 2.03 (creation of a direct financial obligation) and Item 8.01 (other events).

2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 8.01 Other Events

• Second quarter 2026 revenues increased 8.7% to $20.230 billion, from $18.605 billion in Q2 2025.
• Adjusted EBITDA increased 4.6% to $4.027 billion; cash flows from operating activities totaled $2.335 billion, down from $4.210 billion in Q2 2025.
• Payer mix shift from increased uninsured volume had an unfavorable impact on pre-tax income of approximately $400 million in Q2 2026.
• Company revised 2026 guidance: revenues $77.0-$79.5 billion, net income $6.3-$6.7 billion, Adjusted EBITDA $15.4-$16.1 billion, EPS $28.70-$30.50.
• Board declared quarterly cash dividend of $0.78 per share, payable September 30, 2026.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits

• Net income attributable to HCA Healthcare expected to be approximately $1.699 billion, or $7.62 per diluted share, compared to $1.653 billion, or $6.83 per diluted share, in Q2 2025.
• Adjusted EBITDA expected to be approximately $4.027 billion for Q2 2026, compared to $3.849 billion in Q2 2025.
• Same facility admissions increased 2.5% and same facility equivalent admissions increased 2.7% year-over-year.
• 2026 guidance revised: revenues $77.000-$79.500 billion, net income $6.300-$6.700 billion, Adjusted EBITDA $15.400-$16.100 billion, EPS $28.70-$30.50 per diluted share.
• Payer mix shift from health insurance exchanges had an unfavorable impact of approximately $400 million on income before income taxes in Q2 2026.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Dr. Michael Cuffe agreed on June 15, 2026, to step down as Executive Vice President and Chief Clinical Officer effective August 31, 2026.
• Dr. Cuffe will be eligible for benefits under the company's executive severance policy and applicable incentive plans.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

• The offering comprised $1.0B of 4.700% notes due 2031, $750M of 5.000% notes due 2033, and $1.25B of 5.300% notes due 2036.
• The notes are fully and unconditionally guaranteed on a senior unsecured basis by parent HCA Healthcare, Inc.
• Interest is payable semi-annually on May 15 and November 15, beginning November 15, 2026.
• Holders may require repurchase at 101% of principal upon a change of control combined with a qualifying ratings downgrade.

1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 8.01 Other Events · 9.01 Financial Statements and Exhibits

• All nine director nominees were elected to one-year terms, including Thomas F. Frist III, Samuel N. Hazen, and Nancy-Ann DeParle.
• The appointment of Ernst & Young LLP as independent auditor for 2026 was ratified with 192,731,533 votes for.
• The non-binding advisory resolution on named executive officer compensation was approved with 182,386,619 votes for.
• Two stockholder proposals—on healthcare consequences reporting and on acting by written consent—were not approved.

5.07 Submission of Matters to a Vote of Security Holders

• On April 27, 2026, HCA Healthcare, Inc. announced that its wholly owned subsidiary HCA Inc. proposes to offer senior unsecured notes, with terms to be set at pricing.
• HCA Inc. gave notice to redeem all $1.500 billion of its 5.250% senior notes due June 2026 and all $1.000 billion of its 5.375% senior notes due September 2026, on May 27, 2026, conditioned on receiving offering proceeds.
• Citigroup Global Markets Inc., Barclays Capital Inc., BofA Securities, Inc., and J.P. Morgan Securities LLC are joint book-running managers for the offering.
• The offering is made under an effective shelf registration statement; the press release is included as Exhibit 99.1 to the 8-K.

8.01 Other Events · 9.01 Financial Statements and Exhibits

• Net income attributable to HCA Healthcare, Inc. was $1.620 billion, or $7.15 per diluted share, up 0.6% from $1.610 billion in Q1 2025.
• Adjusted EBITDA increased 1.9% to $3.802 billion in Q1 2026, compared to $3.733 billion in Q1 2025.
• Cash flows from operating activities rose 22.0% to $2.014 billion in Q1 2026, and the company repurchased 3.157 million shares for $1.571 billion.
• The Board declared a quarterly cash dividend of $0.78 per share, payable June 30, 2026, and the company reaffirmed its 2026 guidance.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits